T 1496/21 (RSV antigens/ID BIOMEDICAL CORPORATION) of 12.10.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T149621.20231012
- Date of decision
- 12 October 2023
- Case number
- T 1496/21
- Online on
- 27 November 2023
- Petition for review of
- -
- Application number
- 16180926.4
- IPC class
- A61K 39/155A61K 39/00A61P 31/14A61P 37/04C12N 15/62C07K 14/005A61K 39/12C07K 14/135C07K 19/00A61K 9/107C12N 15/45A61K 39/295A61K 9/127
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Recombinant RSV antigens
- Applicant name
- ID Biomedical Corporation of Quebec
GlaxoSmithKline Biologicals s.a. - Opponent name
- Janssen Vaccines & Prevention B.V.
Pfizer Inc. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 83
- Keywords
- Sufficiency of disclosure - (no)
- Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.